Trial Profile
Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibitor in Patients With Triple Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Ductal carcinoma; Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 15 Jun 2023 Planned End Date changed from 28 Feb 2023 to 31 Dec 2025.
- 15 Jun 2023 Planned primary completion date changed from 28 Feb 2023 to 31 Dec 2025.
- 01 Jun 2023 Results published in the Breast Cancer Research and Treatment